Capricor Therapeutics shares are trading higher after the company announced it will present 24-month Phase 3 HOPE-3 data for its Duchenne muscular dystrophy drug, Deramiocel, following a major BLA amendment submitted to the FDA ahead of its November 22 PDUFA date.